Taken together, these data indicate that Pum1 or/and Pum2 siRNA delivery by nanoparticles prevented further growth of CRC in vivo, and that Pum1/2 are potential targets for the treatment of CRC. The gene discussed is PUM1; the disease is colorectal carcinoma.